This site is intended for healthcare professionals
Latest drug news
  • Home
  • /
  • News
  • /
  • 2021
  • /
  • 5
  • /
  • CHMP recommends Ozawade for the treatment of exces...
News

CHMP recommends Ozawade for the treatment of excessive daytime sleepiness in obstructive sleep apnoea.- Bioproject Pharma

Read time: 1 mins
Published:25th May 2021
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Ozawade (pitolisant), intended for the treatment of excessive daytime sleepiness in obstructive sleep apnoea.

The applicant for this medicinal product is Bioproject Pharma. The benefits of Ozawade are its ability to improve wakefulness in patients with obstructive sleep apnoea. The most common side effects are headache and insomnia..

Condition: Sleeping Disorders
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.